Mustafa Jawad Al-Imari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mustafa Jawad Al-Imari has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Karrar Salih Mahdi
Medical Laboratory Techniques Department, Al-Mustaqbal University College, 51001 Hillah, Babil, Iraq
2 shared publications - Abed Saif Alghawli
Computer Science Department, College of Sciences and Humanities, Prince Sattam Bin Abdulaziz University, Aflaj 16278, Saudi Arabia
1 shared publication - Ahmed Musa Dinar
Computer Engineering Department, University of Technology- Iraq, Baghdad 19006, Iraq
1 shared publication - Alaa Sulaiman Al Waisy
Computer Technologies Engineering Department, Information Technology College, Imam Ja’afar Al-Sadiq University, Baghdad 10001, Iraq
1 shared publication - Amna Shaker Mahdi
University of Basrah
1 shared publication Farah Safaa Abdulhussein Alwan
Medical Laboratory Techniques Department, Al-Mustaqbal University College, 51001 Hillah, Babil, Iraq
1 shared publication
Latest Publications
- Open Access
- 29 September 2026
- Published by AMALTEA Medical Publishing House in Romanian Journal of Rheumatology
- Vol. 35 (3) , 194
Association between mean platelet volume and disease activity in systemic lupus erythematosus: comparison with anti-dsDNA antibodies
Background. Mean platelet volume (MPV) is routinely reported in the complete blood count; however, its role in determining disease activity in systemic lupus erythematosus (SLE) remains unclear. Objectives. To explore the association between MPV and SLE disease activity and to assess whether MPV can distinguish active from inactive disease in comparison with anti-double-stranded DNA (anti-dsDNA) antibodies. Methods. A total of 100 patients with SLE (54 with active and 46 with inactive disease) and 40 healthy controls were enrolled in this cross-sectional study. The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) was used to evaluate disease activity. MPV, erythrocyte sedimentation rate (ESR), complement C3 and C4, and anti-dsDNA levels were assessed. Correlation analysis was used to assess associations between laboratory parameters and disease activity. Receiver operating characteristic (ROC) analysis was used to assess the ability of MPV and anti-dsDNA to distinguish active from inactive SLE. Results. Mean MPV was lower in patients with SLE than in healthy controls (8.15 ± 1.45 vs. 9.85 ± 1.12 fL, p < 0.001). Patients with active SLE exhibited lower MPV, C3, and C4 levels and higher anti-dsDNA and ESR levels compared with patients with inactive SLE. MPV was inversely correlated with SLEDAI (r = −0.82, p < 0.001) and anti-dsDNA (r = −0.58, p < 0.001), whereas anti-dsDNA showed a positive correlation with SLEDAI (r = 0.68, p < 0.001). The area under the curve (AUC) was 0.78 for MPV and 0.89 for anti-dsDNA. Conclusions. Higher disease activity in patients with SLE was associated with lower MPV. MPV was less discriminative than anti-dsDNA in distinguishing between active and inactive disease, but it is readily available and could be a valuable addition to the parameters used to assess disease activity.
- 29 September 2026
- Published by AMALTEA Medical Publishing House in Romanian Journal of Rheumatology
- Vol. 35 (3) , 194
Open AccessAssociation between mean platelet volume and disease activity in systemic lupus erythematosus: comparison with anti-dsDNA antibodies
Background. Mean platelet volume (MPV) is routinely reported in the complete blood count; however, its role in determining disease activity in systemic lupus erythematosus (SLE) remains unclear. Objectives. To explore the association between MPV and SLE disease activity and to assess whether MPV can distinguish active from inactive disease in comparison with anti-double-stranded DNA (anti-dsDNA) antibodies. Methods. A total of 100 patients with SLE (54 with active and 46 with inactive disease) and 40 healthy controls were enrolled in this cross-sectional study. The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) was used to evaluate disease activity. MPV, erythrocyte sedimentation rate (ESR), complement C3 and C4, and anti-dsDNA levels were assessed. Correlation analysis was used to assess associations between laboratory parameters and disease activity. Receiver operating characteristic (ROC) analysis was used to assess the ability of MPV and anti-dsDNA to distinguish active from inactive SLE. Results. Mean MPV was lower in patients with SLE than in healthy controls (8.15 ± 1.45 vs. 9.85 ± 1.12 fL, p < 0.001). Patients with active SLE exhibited lower MPV, C3, and C4 levels and higher anti-dsDNA and ESR levels compared with patients with inactive SLE. MPV was inversely correlated with SLEDAI (r = −0.82, p < 0.001) and anti-dsDNA (r = −0.58, p < 0.001), whereas anti-dsDNA showed a positive correlation with SLEDAI (r = 0.68, p < 0.001). The area under the curve (AUC) was 0.78 for MPV and 0.89 for anti-dsDNA. Conclusions. Higher disease activity in patients with SLE was associated with lower MPV. MPV was less discriminative than anti-dsDNA in distinguishing between active and inactive disease, but it is readily available and could be a valuable addition to the parameters used to assess disease activity.
- Open Access
- 28 November 2022
- Published by Hindawi Limited in Computational Intelligence and Neuroscience
- Vol. 2022, 1-12
Cell Phenotype Classification Based on Joint of Texture Information and Multilayer Feature Extraction in DenseNet
Cell phenotype classification is a critical task in many medical applications, such as protein localization, gene effect identification, and cancer diagnosis in some types. Fluorescence imaging is the most efficient tool to analyze the biological characteristics of cells. So cell phenotype classification in fluorescence microscopy images has received increased attention from scientists in the last decade. The visible structures of cells are usually different in terms of shape, texture, relationship between intensities, etc. In this scope, most of the presented approaches use one type or joint of low-level and high-level features. In this paper, a new approach is proposed based on a combination of low-level and high-level features. An improved version of local quinary patterns is used to extract low-level texture features. Also, an innovative multilayer deep feature extraction method is performed to extract high-level features from DenseNet. In this respect, an output feature map of dense blocks is entered in a separate way to pooling and flatten layers, and finally, feature vectors are concatenated. The performance of the proposed approach is evaluated on the benchmark dataset 2D-HeLa in terms of accuracy. Also, the proposed approach is compared with state-of-the-art methods in terms of classification accuracy. Comparison of results demonstrates higher performance of the proposed approach in comparison with some efficient methods.
- 28 November 2022
- Published by Hindawi Limited in Computational Intelligence and Neuroscience
- Vol. 2022, 1-12
Open AccessCell Phenotype Classification Based on Joint of Texture Information and Multilayer Feature Extraction in DenseNet
Cell phenotype classification is a critical task in many medical applications, such as protein localization, gene effect identification, and cancer diagnosis in some types. Fluorescence imaging is the most efficient tool to analyze the biological characteristics of cells. So cell phenotype classification in fluorescence microscopy images has received increased attention from scientists in the last decade. The visible structures of cells are usually different in terms of shape, texture, relationship between intensities, etc. In this scope, most of the presented approaches use one type or joint of low-level and high-level features. In this paper, a new approach is proposed based on a combination of low-level and high-level features. An improved version of local quinary patterns is used to extract low-level texture features. Also, an innovative multilayer deep feature extraction method is performed to extract high-level features from DenseNet. In this respect, an output feature map of dense blocks is entered in a separate way to pooling and flatten layers, and finally, feature vectors are concatenated. The performance of the proposed approach is evaluated on the benchmark dataset 2D-HeLa in terms of accuracy. Also, the proposed approach is compared with state-of-the-art methods in terms of classification accuracy. Comparison of results demonstrates higher performance of the proposed approach in comparison with some efficient methods.
- Open Access
- 8 September 2022
- Published by MDPI AG in Bioengineering
- Vol. 9 (9) , 457
MEF: Multidimensional Examination Framework for Prioritization of COVID-19 Severe Patients and Promote Precision Medicine Based on Hybrid Multi-Criteria Decision-Making Approaches
Effective prioritization plays critical roles in precision medicine. Healthcare decisions are complex, involving trade-offs among numerous frequently contradictory priorities. Considering the numerous difficulties associated with COVID-19, approaches that could triage COVID-19 patients may help in prioritizing treatment and provide precise medicine for those who are at risk of serious disease. Prioritizing a patient with COVID-19 depends on a variety of examination criteria, but due to the large number of these biomarkers, it may be hard for medical practitioners and emergency systems to decide which cases should be given priority for treatment. The aim of this paper is to propose a Multidimensional Examination Framework (MEF) for the prioritization of COVID-19 severe patients on the basis of combined multi-criteria decision-making (MCDM) methods. In contrast to the existing literature, the MEF has not considered only a single dimension of the examination factors; instead, the proposed framework included different multidimensional examination criteria such as demographic, laboratory findings, vital signs, symptoms, and chronic conditions. A real dataset that consists of data from 78 patients with different examination criteria was used as a base in the construction of Multidimensional Evaluation Matrix (MEM). The proposed framework employs the CRITIC (CRiteria Importance Through Intercriteria Correlation) method to identify objective weights and importance for multidimensional examination criteria. Furthermore, the VIKOR (VIekriterijumsko KOmpromisno Rangiranje) method is utilized to prioritize COVID-19 severe patients. The results based on the CRITIC method showed that the most important examination criterion for prioritization is COVID-19 patients with heart disease, followed by cough and nasal congestion symptoms. Moreover, the VIKOR method showed that Patients 8, 3, 9, 59, and 1 are the most urgent cases that required the highest priority among the other 78 patients. Finally, the proposed framework can be used by medical organizations to prioritize the most critical COVID-19 patient that has multidimensional examination criteria and to promptly give appropriate care for more precise medicine.
- 8 September 2022
- Published by MDPI AG in Bioengineering
- Vol. 9 (9) , 457
Open AccessMEF: Multidimensional Examination Framework for Prioritization of COVID-19 Severe Patients and Promote Precision Medicine Based on Hybrid Multi-Criteria Decision-Making Approaches
Effective prioritization plays critical roles in precision medicine. Healthcare decisions are complex, involving trade-offs among numerous frequently contradictory priorities. Considering the numerous difficulties associated with COVID-19, approaches that could triage COVID-19 patients may help in prioritizing treatment and provide precise medicine for those who are at risk of serious disease. Prioritizing a patient with COVID-19 depends on a variety of examination criteria, but due to the large number of these biomarkers, it may be hard for medical practitioners and emergency systems to decide which cases should be given priority for treatment. The aim of this paper is to propose a Multidimensional Examination Framework (MEF) for the prioritization of COVID-19 severe patients on the basis of combined multi-criteria decision-making (MCDM) methods. In contrast to the existing literature, the MEF has not considered only a single dimension of the examination factors; instead, the proposed framework included different multidimensional examination criteria such as demographic, laboratory findings, vital signs, symptoms, and chronic conditions. A real dataset that consists of data from 78 patients with different examination criteria was used as a base in the construction of Multidimensional Evaluation Matrix (MEM). The proposed framework employs the CRITIC (CRiteria Importance Through Intercriteria Correlation) method to identify objective weights and importance for multidimensional examination criteria. Furthermore, the VIKOR (VIekriterijumsko KOmpromisno Rangiranje) method is utilized to prioritize COVID-19 severe patients. The results based on the CRITIC method showed that the most important examination criterion for prioritization is COVID-19 patients with heart disease, followed by cough and nasal congestion symptoms. Moreover, the VIKOR method showed that Patients 8, 3, 9, 59, and 1 are the most urgent cases that required the highest priority among the other 78 patients. Finally, the proposed framework can be used by medical organizations to prioritize the most critical COVID-19 patient that has multidimensional examination criteria and to promptly give appropriate care for more precise medicine.
- Open Access
- 28 April 2022
- Published by Universidad Tecnica de Manabi in International journal of health sciences
- p. 6292-6308
Repaglinide and metformin (diabetic treatments) enhance sexual efficiency
Diabetes mellitus type 2 (DMT2) is one of the modern societies’ highest public health threats. For a while, it was believed that DM had no impact on male reproductive function; however, new research has cast doubt on that assumption. To find out whether repaglinide and metformin may improve sperm motility and testosterone levels in diabetic and non-diabetic albino rats, researchers in this study used these two drugs to treat diabetes. Methods: Alloxan injections at three dosages of 120 mg/kg intraperitoneal produced type 2 diabetes in male rats. Experimental rats were classified into two main groups. The first group included four subgroups of male rats treated with alloxan (DM inducer). Each subgroup contained seven rats “1. Control without any treatment (positive control), 2. treated by 500 mg/kg metformin, 3. treated by 4 mg/kg repaglinide, and 4. treated by 500 mg/kg metformin and 4 mg/kg repaglinide”. The second group also includes four subgroups but without alloxan treated. Each subgroup has seven rats; all are categorized in the same initial group and receive identical treatment dosages.
- 28 April 2022
- Published by Universidad Tecnica de Manabi in International journal of health sciences
- p. 6292-6308
Open AccessRepaglinide and metformin (diabetic treatments) enhance sexual efficiency
Diabetes mellitus type 2 (DMT2) is one of the modern societies’ highest public health threats. For a while, it was believed that DM had no impact on male reproductive function; however, new research has cast doubt on that assumption. To find out whether repaglinide and metformin may improve sperm motility and testosterone levels in diabetic and non-diabetic albino rats, researchers in this study used these two drugs to treat diabetes. Methods: Alloxan injections at three dosages of 120 mg/kg intraperitoneal produced type 2 diabetes in male rats. Experimental rats were classified into two main groups. The first group included four subgroups of male rats treated with alloxan (DM inducer). Each subgroup contained seven rats “1. Control without any treatment (positive control), 2. treated by 500 mg/kg metformin, 3. treated by 4 mg/kg repaglinide, and 4. treated by 500 mg/kg metformin and 4 mg/kg repaglinide”. The second group also includes four subgroups but without alloxan treated. Each subgroup has seven rats; all are categorized in the same initial group and receive identical treatment dosages.
- Open Access
- 1 January 2019
- Published by Diva Enterprises Private Limited in Indian Journal of Public Health Research & Development
- Vol. 10 (2) , 778-783
Anti-Glutamic acid Decarboxylase Autoantibody as Biomarker for Diagnosis of Type 1DM Patients in Iraq
Background Type 1 diabetes mellitus (T1DM), also known as autoimmune diabetes, is a chronic disease characterized by insulin deficiency due to pancreatic β-cell loss and leads to hyperglycaemia. The T cell-mediated destruction of β-cells is-targeting insulin, glutamic acid decarboxylase (GAD), insulinoma-associated protein 2 and zinc transporter. The GAD biomarker of T1DM is found months to years before symptoms onset and can be used to identify and study individuals who are at risk for developing T1DM. Objective To evaluate the role of GAD in diagnosis of T1DM and to compare the new diagnostic marker, anti-GAD, associations with future disease activity and compared to type 2 DM. Material and Method This study involved fifty six (56) blood and serum samples from patients suffering from T1DM, (12) patients with type 2DM and (12) healthy individuals as controls. The average disease duration was 6.5±0.5 years (1-15years). Anti-GAD antibody assayed as biomarker parameter for all subjects. Anti-GAD as it was tested by Chorus device (ELISA automated device) as semi quantitative determination. All clinical features were investigated by questionnaire interviews. Data were presented as frequencies and percentages. Results Male patients with T1DM appeared to be more affected than women. The results also showed elevated levels of anti-GAD in 51.8% of T1DM. In a random sample of (12) non-diabetic individuals, none had anti-GAD. The sensitivity of the anti-GAD test for T1DM was 82.2% and the specificity was 93%. Conclusion Prevalence of Anti-GAD is associated with age. Patients with Type 1DM (Children and adolescents) had increased prevalence of Anti-GAD antibodies. The positivity of anti-GAD antibodies was higher in children and adolescents and less frequent in adult patients involved in this study. So it could be a useful serological assay in establishing the diagnosis of type 1DM and prediction of very high risk for development of T1DM.
- 1 January 2019
- Published by Diva Enterprises Private Limited in Indian Journal of Public Health Research & Development
- Vol. 10 (2) , 778-783
Open AccessAnti-Glutamic acid Decarboxylase Autoantibody as Biomarker for Diagnosis of Type 1DM Patients in Iraq
Background Type 1 diabetes mellitus (T1DM), also known as autoimmune diabetes, is a chronic disease characterized by insulin deficiency due to pancreatic β-cell loss and leads to hyperglycaemia. The T cell-mediated destruction of β-cells is-targeting insulin, glutamic acid decarboxylase (GAD), insulinoma-associated protein 2 and zinc transporter. The GAD biomarker of T1DM is found months to years before symptoms onset and can be used to identify and study individuals who are at risk for developing T1DM. Objective To evaluate the role of GAD in diagnosis of T1DM and to compare the new diagnostic marker, anti-GAD, associations with future disease activity and compared to type 2 DM. Material and Method This study involved fifty six (56) blood and serum samples from patients suffering from T1DM, (12) patients with type 2DM and (12) healthy individuals as controls. The average disease duration was 6.5±0.5 years (1-15years). Anti-GAD antibody assayed as biomarker parameter for all subjects. Anti-GAD as it was tested by Chorus device (ELISA automated device) as semi quantitative determination. All clinical features were investigated by questionnaire interviews. Data were presented as frequencies and percentages. Results Male patients with T1DM appeared to be more affected than women. The results also showed elevated levels of anti-GAD in 51.8% of T1DM. In a random sample of (12) non-diabetic individuals, none had anti-GAD. The sensitivity of the anti-GAD test for T1DM was 82.2% and the specificity was 93%. Conclusion Prevalence of Anti-GAD is associated with age. Patients with Type 1DM (Children and adolescents) had increased prevalence of Anti-GAD antibodies. The positivity of anti-GAD antibodies was higher in children and adolescents and less frequent in adult patients involved in this study. So it could be a useful serological assay in establishing the diagnosis of type 1DM and prediction of very high risk for development of T1DM.